Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $1.9 million.

  • Agios Pharmaceuticals' Change in Accured Expenses rose 15612.81% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 3880.01%. This contributed to the annual value of $3.7 million for FY2024, which is 7117.89% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $1.9 million for Q3 2025, which was up 15612.81% from $14.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Change in Accured Expenses high stood at $14.5 million for Q2 2025, and its period low was -$26.1 million during Q1 2025.
  • Over the past 5 years, Agios Pharmaceuticals' median Change in Accured Expenses value was $1.9 million (recorded in 2025), while the average stood at $522947.4.
  • In the last 5 years, Agios Pharmaceuticals' Change in Accured Expenses skyrocketed by 124416.67% in 2022 and then crashed by 36402.77% in 2024.
  • Agios Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $2.7 million in 2021, then skyrocketed by 90.78% to $5.2 million in 2022, then skyrocketed by 143.13% to $12.7 million in 2023, then increased by 6.92% to $13.6 million in 2024, then tumbled by 85.78% to $1.9 million in 2025.
  • Its Change in Accured Expenses stands at $1.9 million for Q3 2025, versus $14.5 million for Q2 2025 and -$26.1 million for Q1 2025.